Abstract
In 65 patients with systemic breast cancer, a biochemical response index using three tumour markers in combination, carcinoembryonic antigen (CEA), carbohydrate antigen 15-3 (CA 15-3) and erythrocyte sedimentation rate (ESR), allowed objective biochemical assessment of response to endocrine therapy. Changes in these three markers at 2, 4 and 6 months showed a highly significant correlation with UICC assessed response at 6 months. At 4 months, changes in these three markers resulted in a selectivity of 93%, with a sensitivity of 92% and a specificity of 82%. Survival of groups of patients assessed biochemically or by UICC criteria for non-progression or progression showed no significant difference. The advantage of the biochemical assessment are that it is objective and reproducible. The assessment gives similar information to the UICC assessment but can be carried out earlier. Changes in the three markers appears to reflect the dynamics of change in tumour mass in response to systemic therapy in contrast to the UICC criteria which reflect structural change.
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Robertson, J., Pearson, D., Price, M. et al. Objective measurement of therapeutic response in breast cancer using tumour markers. Br J Cancer 64, 757–763 (1991). https://doi.org/10.1038/bjc.1991.394
Issue Date:
DOI: https://doi.org/10.1038/bjc.1991.394
- Springer Nature Limited
This article is cited by
-
Bony metastases from breast cancer - a study of foetal antigen 2 as a blood tumour marker
World Journal of Surgical Oncology (2010)
-
Development and verification of a prediction model using serum tumor markers to predict the response to chemotherapy of patients with metastatic or recurrent breast cancer
Journal of Cancer Research and Clinical Oncology (2008)
-
Correlation study of Carcino Embryonic Antigen & Cancer Antigen 15.3 in pretreated female breast cancer patients
Indian Journal of Clinical Biochemistry (2007)
-
Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer
British Journal of Cancer (2004)
-
Serum CEA and CA 15-3 as prognostic factors in primary breast cancer
British Journal of Cancer (2002)